ArticleGastroenterology and hepatology from bed to bench2025
Could serum uric acid levels be a biomarker for metabolic dysfunction-associated steatotic liver disease?
Article in Gastroenterology and hepatology from bed to bench, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: In this study, we investigated the relationship between serum uric acid (SUA) and metabolic dysfunction-associated steatotic liver disease (MASLD) in patients detected through abdominal ultrasound. The second aim was to determine if there were any gender differences. Background: High SUA levels may contribute to the mechanisms underlying various metabolic disorders, including MASLD. Methods: We conducted a retrospective study among patients older than 18 who had been admitted to a tertiary hospital's gastroenterology outpatient clinic for over two years. A total of 200 patients diagnosed with either Grade 1, 2, or 3 hepatosteatosis by ultrasound screening and 200 patients without hepatosteatosis were included in the study. Patients' demographic features, laboratory parameters, and detailed medical history were extracted from the hospital's medical records. Results: The mean age of the 400 patients enrolled in the study was 47.92±0.78 years, and 70.25% were men. SUA (5.34 mg/dL ± 1.52 vs. 4.64 mg/dL ± 1.28, p=0.001), alanine aminotransferase (ALT) (26.55 U/L ± 23.82 vs. 19.57 U/L ± 20.81, p=0.002), aspartate aminotransferase (AST) (22.68 U/L ± 20.35 vs. 18.07 U/L ± 9.89, p=0.005), and glycosylated hemoglobin (HbA1c) (6.45% ± 1.69 vs. 5.76% ± 1.23, p=0.001) levels were higher in the MASLD group. In the MASLD group, HbA1c, AST, and ALT were significantly higher in the Grade 2-3 group than in the Grade 1 (p=0.038, p=0.038, p=0.001, respectively). Conclusion: Elevated SUA levels are strongly linked to MASLD, particularly in males. Ease of measurement and low cost suggest that SUA could serve as a non-invasive biomarker for MASLD detection in at-risk groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.